← Eichor
Condition: Moderate To Severe Atopic Dermatitis Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Moderate To Severe Atopic Dermatitis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
Phase 2 · 62 location(s) · Janssen Research & Development, LLC · NCT07230860Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
Phase 2 · 23 location(s) · Enveda Therapeutics · NCT07298395FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
Phase 1 · 5 location(s) · Pfizer · NCT06564389Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
Phase 3 · 1 location(s) · Jiangsu vcare pharmaceutical technology co., LTD · NCT06723080A Phase I Study of SSGJ-716 in Healthy Adults and Participants With Moderate-to-Severe Atopic Dermatitis
Phase 1 · 1 location(s) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · NCT07693738Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe At
Phase 2 · 99 location(s) · Novartis Pharmaceuticals · NCT06947993Lebrikizumab in Moderate-to-severe Atopic Dermatitis
Phase 4 · 4 location(s) · Johann E Gudjonsson MD PhD · NCT06906497Treatment and Medical Care of Patients With Moderate-to-severe Atopic Dermatitis - TREATswitzerland
Phase N/A · 9 location(s) · Swiss Society of Dermatology and Venereology · NCT05819463Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.
Phase 3 · 30 location(s) · medac GmbH · NCT06239311The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit
Phase N/A · 7 location(s) · Sanofi · NCT07467564A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moder
Phase 2 · 2 location(s) · AbbVie · NCT06524635A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupil
Phase 3 · 128 location(s) · AbbVie · NCT06389136A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and
Phase 3 · 72 location(s) · LEO Pharma · NCT06311682Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impact
Phase N/A · 2 location(s) · University Hospital Schleswig-Holstein · NCT07444801TREATgermany: German National Clinical Registry for Patients With Moderate-to-severe Atopic Dermatitis
Phase N/A · 3 location(s) · Technische Universität Dresden · NCT03057860Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis
Phase 4 · 1 location(s) · Northwestern University · NCT05042258A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis
Phase 2 · 1 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT07399067A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
Phase 2 · 85 location(s) · Apollo Therapeutics Ltd · NCT07599813A Clinical Study to Evaluate SM17 for Atopic Dermatitis
Phase 2 · 1 location(s) · SinoMab BioScience Ltd · NCT07445919A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis
Phase N/A · 1 location(s) · Pfizer · NCT05391061A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.
Phase N/A · 30 location(s) · Pfizer · NCT05689151Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
Phase N/A · 108 location(s) · Galderma R&D · NCT06988605Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
Phase 1 · 1 location(s) · Arcutis Biotherapeutics, Inc. · NCT07453602A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis
Phase 1 · 14 location(s) · Sitryx Therapeutics Ltd · NCT07558668Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis
Phase 3 · 3 location(s) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · NCT07042126A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Phase 2 · 23 location(s) · Inmagene LLC · NCT07037901TREAT NL (TREatment of ATopic Eczema, the Netherlands) Registry: Dutch National Registry for Patients With Moderate-to-s
Phase N/A · 1 location(s) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC · NCT03621137An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Modera
Phase N/A · 38 location(s) · AbbVie · NCT06421740Evaluation of Efficacy and Safety of Oral Roflumilast for Treatment of Moderate to Severe Atopic Dermatitis in Patients
Phase 2 · 1 location(s) · Nora Mohamed Abdelrazik · NCT07297602Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
Phase 2 · 1 location(s) · Corvus Pharmaceuticals, Inc. · NCT07441395
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.